Melanoma staging: facts and controversies

Area of Science:

• Oncology
• Dermatology

Background:

• The utility of staging examinations for initial melanoma diagnosis and surveillance is controversial.
• Melanoma recurrence and progression risks vary significantly across different risk groups.

Purpose of the Study:

• To evaluate the role of staging examinations in melanoma management.
• To stratify recommendations for staging and surveillance based on patient risk groups.

Main Methods:

• Review of current practices and evidence for melanoma staging.
• Categorization of patients into low (Stage IA), intermediate (Stages IB-IIA), high (Stages IIB-III), and very high (Stage IV) risk groups.
• Recommendations for diagnostic and surveillance procedures tailored to each risk group.

Main Results:

• Low-risk patients (Stage IA) generally do not require extensive staging beyond baseline assessment.
• Intermediate-risk patients (Stages IB-IIA) benefit from initial staging including sentinel lymph node biopsy (SLNB) and CT scans, with follow-up including physical exams, S100beta blood tests, and lymph node ultrasound.
• High-risk patients (Stages IIB-III) require initial CT staging and regular 6-month follow-up with whole-body imaging (CT/MRI), physical exams, S100beta tests, and lymph node ultrasound, potentially enabling metastasis removal in 15-25% of cases.
• Stage IV melanoma management is individualized due to high recurrence and progression risk.

Conclusions:

• Staging and surveillance strategies for melanoma should be risk-stratified.
• Tailored staging examinations can optimize patient management and prognosis, particularly in higher-risk melanoma patients.
• Intensified follow-up in high-risk patients may improve outcomes through early detection of metastases.